Present status and perspectives of cell-based therapies for liver diseases
Andreas K. Nüssler(Fresenius (Germany)), Jan G. Hengstler(Johannes Gutenberg University Mainz), Étienne Sokal(UCLouvain), Bruno Christ(Leipzig University), Michael Ott(Center for Experimental and Clinical Infection Research), G. Gäbelein(Charité - Universitätsmedizin Berlin), Michael Manns(Medizinische Hochschule Hannover), Maren Schulze, Wiebke Schormann(Leipzig University), Steven Strom(University of Pittsburgh), Ewa Ellis(University of Pittsburgh), Matthias Kraemer(IWW Water Centre), Wolfgang E. Thasler(LMU Klinikum), Wolfgang E. Fleig(Mayo Clinic), Frank Nocken(Neovii Biotech (Germany)), Sarah König(University of Göttingen), Marc Brulport(Leipzig University)
Cited by 205
Related Papers
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
|Journal of Clinical Oncology|2006|1.2k
Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
|Clinical Cancer Research|2012|382
Hepatocellular Carcinoma (HCC)
|Journal of Clinical Gastroenterology|2010|322